Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):   July 7, 2011

Anadys Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware 000-50632 22-3193172
(State or other jurisdiction
(I.R.S. Employer
of incorporation) File Number) Identification No.)
5871 Oberlin Drive, Suite 200, San Diego, California   92121
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:   (858) 530-3600

Not Applicable
Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

Anadys Pharmaceuticals, Inc. (the "Company") is reporting that enrollment has been completed in the Phase IIb study of setrobuvir (ANA598), in which setrobuvir is being tested in combination with pegylated interferon and ribavirin in hepatitis C patients. The Company anticipates that all patients in the study will have completed their 12 week visit by the end of the third quarter of 2011 and plans to release preliminary 12 week data shortly thereafter.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Anadys Pharmaceuticals, Inc.
July 7, 2011   By:   Peter T. Slover
        Name: Peter T. Slover
        Title: Vice President, Finance and Operations